- Home
- Results news
- Anuh Pharma
- Q4 FY25 results
Anuh Pharma Q4 FY25 results: net profit down 18.9% to ₹12.46 crore, revenue up 20.9%
Anuh Pharma Limited reported standalone Q4 FY25 revenue of ₹198.14 crore, up 20.9% from Q4 FY24, while net profit fell 18.9% to ₹12.46 crore. EBITDA was ₹18.67 crore, with the margin declining to 9.4% from 11.7%, as higher expenses outweighed revenue growth; basic EPS was ₹2.49.
Key points
- Standalone Q4 FY25 revenue was ₹198.14 crore, up 20.9% from ₹163.89 crore in Q4 FY24 and 24.2% from ₹159.51 crore in Q3 FY25.
- EBITDA was ₹18.67 crore, down 2.9% year on year from ₹19.22 crore, while the margin fell 2.3 percentage points to 9.4%.
- Net profit was ₹12.46 crore, down 18.9% from ₹15.36 crore in Q4 FY24 but up 20.5% from ₹10.34 crore in Q3 FY25.
- Basic EPS was ₹2.49, compared with ₹3.06 in Q4 FY24 and ₹2.06 in Q3 FY25; there was no exceptional item.
- For FY25, revenue was ₹661.51 crore, up 2.2%, while PAT was ₹47.35 crore, down 21.2%, and basic EPS was ₹9.45.
How did Anuh Pharma perform in Q4 FY25?
Anuh Pharma reported standalone revenue of ₹198.14 crore in Q4 FY25, up 20.9% from ₹163.89 crore in Q4 FY24 and 24.2% from ₹159.51 crore in Q3 FY25. EBITDA was ₹18.67 crore, down 2.9% from ₹19.22 crore a year earlier but up 26.2% from ₹14.79 crore in the previous quarter. The EBITDA margin was 9.4%, compared with 11.7% in Q4 FY24 and 9.3% in Q3 FY25.
Profit before tax was ₹17.28 crore in Q4 FY25, down 12.4% from ₹19.72 crore in Q4 FY24 and up 30.2% from ₹13.27 crore in Q3 FY25. Net profit was ₹12.46 crore, down 18.9% from ₹15.36 crore year on year but up 20.5% from ₹10.34 crore sequentially; basic EPS was ₹2.49 against ₹3.06 and ₹2.06. The PAT margin was 6.3%, down 3.1 percentage points from Q4 FY24 and 0.2 percentage points from Q3 FY25. The reported figures are on a standalone basis; the filing also includes consolidated results.
Total income was ₹199.54 crore, including other income of ₹1.40 crore, compared with ₹166.71 crore in Q4 FY24 and ₹160.45 crore in Q3 FY25. The year-on-year increase in total income was ₹32.83 crore, or 19.7%, while the sequential increase was ₹39.09 crore, or 24.4%. Total expenses were ₹182.26 crore, including cost of materials of ₹137.92 crore, employee cost of ₹6.85 crore, finance costs of ₹0.03 crore, depreciation of ₹2.76 crore and other expenses of ₹24.16 crore. There was no exceptional item.
| ₹ crore | Q4 FY25 | Q3 FY25 | Q4 FY24 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 198.14 | 159.51 | 163.89 | +20.9% | +24.2% |
| Other income | 1.40 | 0.94 | 2.82 | −50.4% | +48.9% |
| Total expenses | 182.26 | 147.19 | 147 | +24.0% | +23.8% |
| EBITDA | 18.67 | 14.79 | 19.22 | −2.9% | +26.2% |
| EBITDA margin | 9.4% | 9.3% | 11.7% | −2.3 pp | +0.1 pp |
| Profit before tax | 17.28 | 13.27 | 19.72 | −12.4% | +30.2% |
| Tax | 4.82 | 2.92 | 4.36 | +10.6% | +65.1% |
| Net profit | 12.46 | 10.34 | 15.36 | −18.9% | +20.5% |
| EPS (₹) | 2.49 | 2.06 | 3.06 | −18.6% | +20.9% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Anuh Pharma's costs and profit?
Against Q4 FY24, total expenses increased by ₹35.26 crore, or 24.0%, to ₹182.26 crore. Cost of materials was higher by ₹20.56 crore, or 17.5%, at ₹137.92 crore; employee cost rose by ₹1.91 crore, or 38.7%, to ₹6.85 crore; depreciation increased by ₹0.53 crore, or 23.8%, to ₹2.76 crore; and other expenses rose by ₹5.08 crore, or 26.6%, to ₹24.16 crore. Finance costs were lower by ₹0.07 crore, or 70.0%, at ₹0.03 crore.
Other income fell by ₹1.42 crore, or 50.4%, to ₹1.40 crore from ₹2.82 crore in Q4 FY24. Profit before tax declined by ₹2.44 crore, or 12.4%, to ₹17.28 crore, while tax expense increased by ₹0.46 crore, or 10.6%, to ₹4.82 crore. Net profit consequently fell by ₹2.90 crore, or 18.9%, to ₹12.46 crore. There was no exceptional item in either quarter, and the filing does not state a reason for the movements in the cost lines.
Sequentially, total expenses rose by ₹35.07 crore, or 23.8%, from ₹147.19 crore in Q3 FY25. Cost of materials increased by ₹19.27 crore, or 16.2%, other expenses by ₹5.45 crore, or 29.1%, employee cost by ₹1.31 crore, or 23.6%, and depreciation by ₹0.58 crore, or 26.6%; finance costs fell by ₹0.25 crore, or 89.3%. Other income increased by ₹0.46 crore, or 48.9%, and tax expense rose by ₹1.90 crore, or 65.1%.
| ₹ crore | Q4 FY25 | Q4 FY24 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 137.92 | 117.36 | +20.56 | +17.5% |
| Employee cost | 6.85 | 4.94 | +1.91 | +38.7% |
| Finance costs | 0.03 | 0.10 | −0.07 | −70.0% |
| Depreciation | 2.76 | 2.23 | +0.53 | +23.8% |
| Other expenses | 24.16 | 19.08 | +5.08 | +26.6% |
| Total expenses | 182.26 | 147 | +35.26 | +24.0% |
| Other income | 1.40 | 2.82 | −1.42 | −50.4% |
| Tax | 4.82 | 4.36 | +0.46 | +10.6% |
Source: Company's results filing (XBRL).
How did Anuh Pharma do in FY25 as a whole?
For the full year FY25, standalone revenue was ₹661.51 crore, up 2.2% from ₹647.0 crore in FY24, while total income was ₹670.97 crore, up 1.8% from ₹659.1 crore. Profit before tax was ₹61.01 crore, down 22.1% from ₹78.31 crore, and net profit was ₹47.35 crore, down 21.2% from ₹60.06 crore.
Basic EPS for FY25 was ₹9.45, down 21.1% from ₹11.98 in FY24. The full-year filing reported revenue from operations of ₹661.51 crore, other income of ₹945.53 lakh, total expenses of ₹60,996.49 lakh, profit before tax of ₹6,100.53 lakh, total tax expenses of ₹1,365.34 lakh and profit after tax of ₹4,735.19 lakh.
| ₹ crore | FY25 | FY24 | Change |
|---|---|---|---|
| Revenue from operations | 661.51 | 647 | +2.2% |
| Profit before tax | 61.01 | 78.31 | −22.1% |
| Net profit | 47.35 | 60.06 | −21.2% |
| EPS (₹) | 9.45 | 11.98 | −21.1% |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
At 31 March 2025, total assets were ₹506.63 crore, compared with ₹434.19 crore at 30 September 2024, while total equity was ₹326.02 crore against ₹303.11 crore. Borrowings were ₹10.5 crore compared with ₹13.57 crore, and cash was ₹19.56 crore against ₹2.97 crore. Inventories were ₹74.48 crore versus ₹71.1 crore, trade receivables were ₹215.87 crore versus ₹183.54 crore, and trade payables were ₹156.84 crore versus ₹101.18 crore.
For FY25, operating cash flow was ₹37.12 crore, compared with ₹12.93 crore in FY24. Investing cash flow was negative ₹19.91 crore, compared with positive ₹0.92 crore, while financing cash flow was negative ₹4.86 crore versus negative ₹8.57 crore. Capital expenditure was ₹19.96 crore in FY25 and ₹4.52 crore in FY24.
| ₹ crore | As of 31 March 2025 | As of 30 September 2024 |
|---|---|---|
| Total assets | 506.63 | 434.19 |
| Total equity | 326.02 | 303.11 |
| Borrowings | 10.50 | 13.57 |
| Cash and equivalents | 19.56 | 2.97 |
| Inventories | 74.48 | 71.10 |
| Trade receivables | 215.87 | 183.54 |
Source: Company's results filing (XBRL).
| ₹ crore | FY25 | FY24 |
|---|---|---|
| Cash from operations | 37.12 | 12.93 |
| Cash from investing | −19.91 | 0.92 |
| Cash from financing | −4.86 | −8.57 |
| Capital expenditure | 19.96 | 4.52 |
Source: Company's results filing (XBRL).
How has Anuh Pharma done over the last 8 quarters?
Across the reported quarters, revenue reached its highest level in Q4 FY25 at ₹198.14 crore and its lowest in Q1 FY25 at ₹137.91 crore. PAT was highest in Q3 FY24 at ₹19.11 crore and lowest in Q1 FY25 at ₹9.51 crore, before rising to ₹12.46 crore in the latest quarter. The EBITDA margin peaked at 13.9% in Q3 FY24 and bottomed at 7.7% in Q1 FY25, then moved to 9.4% in Q4 FY25.
What else did the company announce?
The board approved audited financial results for the quarter and year ended 31 March 2025 and recommended a dividend of ₹1.50 per equity share on post-bonus share capital, representing a 30% payout on the face value of ₹5 each. The dividend was subject to shareholder approval at the AGM, and bonus shares would also be eligible for it.
The board approved a 1:1 bonus issue of one fully paid equity share of ₹5 each for every one fully paid equity share of ₹5 held on the record date, subject to shareholder approval by postal ballot. It also re-appointed Ritesh Bipin Shah and Vivek Bipin Shah as joint managing directors, Bharat Nemchand Shah and Gaurav Satish Shah as directors liable to retire by rotation, and Ankit Kishor Chande as cost auditor for FY26. GHV & Co. was appointed as secretarial auditor for five consecutive years from FY25-26 to FY29-30.
How did Anuh Pharma shares react?
After the filing, the stock was down 0.5% after five minutes and up 1.4% after 15 minutes and 0.6% after 30 minutes. It closed 2.6% higher on the reaction day from its pre-results close. By the next day's close, the stock was up 5.0% from that close, and by five sessions later it was up 8.6%.
| After the filing | Stock | Pharmaceuticals median |
|---|---|---|
| 5 minutes | −0.5% | |
| 15 minutes | +1.4% | |
| 30 minutes | +0.6% | |
| Reaction day | +2.6% | +0.4% |
| Next day | +5.0% | +0.3% |
| 5 days | +8.6% | −0.1% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
How did other Pharmaceuticals companies do?
A total of 155 Pharmaceuticals companies had filed for the quarter, and their median revenue growth was 8.3%. Anuh Pharma's revenue growth of 20.9% was higher than the median; 37 peers grew faster than the company, while 118 peers grew slower than the company. The peer data was recorded as of 6 November 2026.
| Anuh Pharma revenue growth (YoY) | +20.9% |
|---|---|
| Median of 155 other Pharmaceuticals companies | +8.3% |
| Companies with slower revenue growth than Anuh Pharma | 118 of 155 |
| Companies with faster revenue growth than Anuh Pharma | 37 of 155 |
| Companies whose net profit rose | 88 of 155 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Anuh Pharma's revenue in Q4 FY25?
Revenue from operations was ₹198.14 crore, up 20.9% from ₹163.89 crore in Q4 FY24 (standalone).
Did Anuh Pharma make a profit in Q4 FY25?
Yes. Net profit was ₹12.46 crore, against a net profit of ₹15.36 crore in Q4 FY24.
What was Anuh Pharma's EPS in Q4 FY25?
Basic earnings per share were ₹2.49, against ₹3.06 in Q4 FY24.
How did Anuh Pharma shares react to the Q4 FY25 results?
On the reaction day the stock moved +2.6% from the previous close; the median Pharmaceuticals stock moved +0.4%.
When did Anuh Pharma announce its Q4 FY25 results?
On 23 May 2025, in a filing to the NSE.
Sources
- Board Meeting Intimation for Consideration And Approval Of Audited Financial Results For The Financial Year Ended 31St March, 2025, Proposal Of Bonus Issue, If Any And Subject To Approval, And Recommendation Of Final Dividend, If Any, For The Financial Year 2024-25. (BSE, 19 May 2025) · PDF
- Outcome of Board Meeting (NSE, 23 May 2025) · PDF
- Dividend (NSE, 23 May 2025) · PDF
- Outcome of Board Meeting (NSE, 24 May 2025) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.